PRCT Stock Chart & Stats
$357.00
$0.00(0.00%)
At close: 4:00 PM EDT
$357.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$305.01 - $1,217.38
Previous CloseN/A
Volume0.00
Average Volume (3M)177.00
Market Cap
$21.07B
Enterprise Value$1.14B
Total Cash (Recent Filing)$227.91M
Total Debt (Recent Filing)$77.50M
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Nov 04, 2026EPS Estimate
-7.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.94
Shares Outstanding57,273,660
10 Day Avg. Volume0
30 Day Avg. Volume177
Financial Highlights & Ratios
PEG Ratio10.67
Price to Book (P/B)4.78
Price to Sales (P/S)5.67
P/FCF Ratio-29.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$424.69Price Target Upside18.96% Upside
Rating ConsensusHold
Number of Analyst Covering12
EPS Forecast (FY)-31.31
Revenue Forecast (FY)$7.40B
Bulls Say, Bears Say
Bulls Say
Revenue Growth And HYDROS AdoptionRapid revenue and procedure growth, alongside expanding HYDROS placements, indicates increasing clinical adoption and market penetration. A larger installed base can create recurring consumables and service revenue, giving the business a durable foundation for continued scale over the next several quarters.
Gross Margin And Pricing StrengthImproving gross margin and strong system pricing suggest the platform is gaining economic leverage and customer acceptance as volumes grow. If maintained, these factors can support better contribution from each installation and provide a stronger path toward sustainable profitability as operating costs scale.
Clinical And Regulatory ValidationProfessional-society support, completed clinical enrollment, and additional FDA-authorized study activity strengthen Aquablation’s clinical and regulatory position. These milestones can improve physician confidence, support broader adoption, and reinforce the company’s long-term differentiation in BPH treatment.
Bears Say
Persistent Cash BurnSustained and worsening negative operating and free cash flow increases the company’s dependence on its cash balance and future financing capacity. Continued burn could constrain investment flexibility or require additional funding if revenue growth and the planned profitability improvement do not arrive as expected.
Large Operating LossesHigher operating expenses and widening losses show that revenue growth has not yet translated into sustainable earnings. The company expects positive adjusted EBITDA in Q4 2026, but until that transition is demonstrated, elevated spending remains a durable execution and profitability risk.
Legacy AQUABEAM Utilization WeaknessWeakness in legacy AQUABEAM utilization creates a drag while the installed base remains roughly split between AQUABEAM and HYDROS. Management assumed little or no recovery at these sites, leaving a persistent risk to procedure growth, consumables revenue, and upgrade-transition execution.
PROCEPT BioRobotics News
PRCT FAQ
What was PROCEPT BioRobotics’s price range in the past 12 months?
PROCEPT BioRobotics lowest stock price was $305.01 and its highest was $1217.38 in the past 12 months.
What is PROCEPT BioRobotics’s market cap?
PROCEPT BioRobotics’s market cap is $21.07B.
When is PROCEPT BioRobotics’s upcoming earnings report date?
PROCEPT BioRobotics’s upcoming earnings report date is Nov 04, 2026 which is in 8 days.
How were PROCEPT BioRobotics’s earnings last quarter?
PROCEPT BioRobotics released its earnings results on Aug 04, 2026. The company reported -$8.721 earnings per share for the quarter, missing the consensus estimate of -$8.572 by -$0.148.
Is PROCEPT BioRobotics overvalued?
According to Wall Street analysts PROCEPT BioRobotics’s price is currently Undervalued.
Does PROCEPT BioRobotics pay dividends?
PROCEPT BioRobotics does not currently pay dividends.
What is PROCEPT BioRobotics’s EPS estimate?
PROCEPT BioRobotics’s EPS estimate is -7.27.
How many shares outstanding does PROCEPT BioRobotics have?
PROCEPT BioRobotics has 57,273,660 shares outstanding.
What happened to PROCEPT BioRobotics’s price movement after its last earnings report?
PROCEPT BioRobotics reported an EPS of -$8.721 in its last earnings report, missing expectations of -$8.572. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PROCEPT BioRobotics?
Currently, no hedge funds are holding shares in MX:PRCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PROCEPT BioRobotics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$424.69 (18.96% Upside)
$424.69 (18.96% Upside)
Blogger Sentiment
Bullish
MX:PRCT Sentiment 100%
Sector Average 67%
Sector Average 67%
Insider Transactions
Bought Shares
Worth $8.9M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.32%
12-Months-Change
Fundamentals
Return on Equity
-30.62%
Trailing 12-Months
Asset Growth
-6.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
PROCEPT BioRobotics
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
PRCT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a generally positive outlook driven by strong HYDROS adoption, record pricing, solid top-line growth (Q2 revenue +19% and procedures +21% YoY), important clinical and regulatory milestones, and a clear path to positive adjusted EBITDA in Q4 2026. Offsetting risks include a concentrated procedure shortfall in legacy AQUABEAM accounts, higher operating expenses that widened losses in the quarter, and some one-time benefits (tariff recovery) supporting margins. Management is focused on upgrades, scaling launch teams, and patient-activation initiatives to drive durable utilization improvements.View all MX:PRCT earnings summariesPRCT Stock 12 Month Forecast
Average Price Target
$424.69
▲(18.96% Upside)